Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer | Zendy

Elisabetta Zulato | Zendy; Ilaria Attili | Zendy; Alberto Pavan | Zendy; Giorgia Nardo | Zendy; Paola Del Bianco | Zendy; Andrea Boscolo Bragadin | Zendy; Martina Verza | Zendy; Lorenza Pasqualini | Zendy; Giulia Pasello | Zendy; Matteo Fassan | Zendy; Fiorella Calabrese | Zendy; Valentina Guarneri | Zendy; Alberto Amadori | Zendy; Pier Franco Conte | Zendy; Stefano Indraccolo | Zendy

Open Access

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer

Author(s) -

Elisabetta Zulato,

Ilaria Attili,

Alberto Pavan,

Giorgia Nardo,

Paola Del Bianco,

Andrea Boscolo Bragadin,

Martina Verza,

Lorenza Pasqualini,

Giulia Pasello,

Matteo Fassan,

Fiorella Calabrese,

Valentina Guarneri,

Alberto Amadori,

Pier Franco Conte,

Stefano Indraccolo

Publication year - 2020

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/s41416-020-0833-7

Subject(s) - kras , medicine , hazard ratio , oncology , lung cancer , odds ratio , confidence interval , cancer , gastroenterology , colorectal cancer

Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents the most commonly mutated oncogene in Caucasian non-small-cell lung cancer (NSCLC). The aim of this study was to explore association of dynamic plasma KRAS genotyping with outcome in advanced NSCLC patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore